PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Real-world data shows teclistamab can benefit many multiple myeloma patients who would have been ineligible for pivotal trial

Retrospective study revealed efficacy of the bispecific T-cell engager in patients with high-risk, heavily pretreated multiple myeloma, including after prior BCMA therapy

2025-07-09
(Press-News.org) Bottom line: Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial, and identified a novel factor independently associated with outcomes.

Journal in Which the Study was Published: Blood Cancer Discovery, a journal of the American Association for Cancer Research (AACR).

Author: Beatrice M. Razzo, MD

Background: Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation antigen (BCMA) receptor. It received accelerated approval in 2022 for patients treated with four or more lines of prior therapy based on results from the phase I/II MajesTEC-1 clinical trial. However, the potential benefits of the bispecific immunotherapy in populations not represented in the trial, or in the presence of risk factors associated with poorer outcomes, remains an important focus of ongoing clinical investigation.

“Teclistamab is an important treatment option for patients with relapsed/refractory multiple myeloma but there is still a lot to learn about how to modify risk factors and optimize the use of teclistamab in clinical practice,” said Beatrice M. Razzo, MD, an assistant professor at Thomas Jefferson University, former hematology-oncology fellow at the University of Pennsylvania, and the lead author of the real-world study involving patients treated in a consortium of 15 U.S. academic medical centers.

How the Study was Conducted: In the largest study of its kind to date, Razzo and her team retrospectively analyzed data from 509 multiple myeloma patients, half of whom had received at least six prior treatments. Eighty-nine percent (453) of these patients would have been ineligible for MajesTEC-1, with the most common reasons being prior treatment with another BCMA-targeting therapy (236 patients), cytopenias (189 patients), and an ECOG performance status of two or higher (117 patients). Overall, patients in this study represented a higher-risk population, with more frail individuals and a greater prevalence of multidrug refractory disease and cytogenetic abnormalities, according to Razzo.

Results: The bispecific antibody reduced disease burden by at least half in 53% (270) of the 506 evaluable patients, with 45% (228) having at least 90% reduction in disease burden (so-called “very good partial response” in the official response criteria). At a median potential follow-up of 10.1 months, half of patients remained free of progression for at least 5.8 months and an estimated 61% were alive at one year. Even with the high prevalence of patients with high-risk features, there appeared to be no increase in adverse event frequency compared to their prevalence in MajesTEC-1 and other real-world analyses of the bispecific antibody’s use.

Notably, the 56 patients who would have been eligible for MajesTEC-1 had similar overall response rates compared with the registration trial population, 61% and 63%, respectively.

With regard to MajesTEC-1-ineligible patients, the bispecific antibody also benefited many patients previously treated with BCMA-targeting CAR T cells or the antibody-drug conjugate belantamab mafodotin (Blenrep). Forty percent exhibited “very good partial responses,” including 43% of the 58 patients whose disease had been previously treated with the antibody-drug conjugate and 38% of the 104 patients whose disease had previously been treated with CAR T cells.

Further analyses revealed that patients who underwent prior BCMA-targeting therapy within nine months of starting teclistamab-cqyv exhibited lower rates of “very good partial responses” and shorter periods of progression-free survival. However, this therapeutic resistance occurred more often in the group recently treated with CAR T cells than in those recently treated with belantamab mafodotin, who responded at a rate comparable to BCMA therapy-naïve patients.

Author’s Comments: “These findings in patients with prior BCMA CAR T cell exposure suggest that increased spacing may allow for the recovery of T-cell fitness or the reemergence of BCMA-expressing subclones. Alternatively, a longer interval may simply reflect less aggressive disease biology,” explained Razzo.

Extensive pretreatment bone marrow infiltration by myeloma cells (60% fraction or higher) or indirect markers of high disease burden such as anemia, thrombocytopenia, or low absolute lymphocyte count were also significantly associated with lower rates of “very good partial responses” and shorter periods of progression-free survival. The study also found that elevated baseline ferritin was associated with inferior outcomes independently of disease burden.

“Nevertheless, teclistamab-cqyv remains an important treatment option for patients with late-line, relapsed or refractory multiple myeloma, and should be considered even in those with prior BCMA exposure or markers of high disease burden and inflammation.” said Razzo.

“Our results highlight the complex interplay between real-time clinical parameters and baseline disease features in influencing patient outcomes and suggest that the former may be a more reliable indicator of disease biology than the latter in these patients, but there is still a lot to learn,” she added.

To that end, Razzo and her colleagues are focused on their ongoing phase II trial investigating limited-duration drug dosing in patients with advanced multiple myeloma/                 

Study Limitations: Limitations of the study include the nonstandardized nature of the real-world data as well as the lack of a centralized independent review or adjudication process for response and toxicity assessments. Information regarding the dose intensity of teclistamab-cqyv given to patients was also not available for analysis.

Funding & Disclosures: The study was supported by a  National Cancer Institute training grant. Razzo has received advisory board honoraria from Johnson & Johnson.

END


ELSE PRESS RELEASES FROM THIS DATE:

Scientists reveal how a key inflammatory molecule triggers esophageal muscle contraction

2025-07-09
A research group led by Dr. Keisuke Obara, Dr. Kento Yoshioka, and Professor Yoshio Tanaka from the Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University, has uncovered important details about how platelet-activating factor (PAF)—a powerful molecule involved in inflammation and allergic reactions—triggers contractions in the smooth muscles of the esophagus. Their findings could pave the way for new treatments targeting gastrointestinal symptoms associated with allergies, asthma, and anaphylaxis. What is PAF? PAF (platelet-activating factor) is a bioactive lipid molecule produced by various cells in the body, including immune ...

Duration of heat waves accelerating faster than global warming

2025-07-09
Key takeaways Each fraction of a degree of warming will have a bigger impact than the last on lengthening heat waves, with the most extreme heat waves lengthening the most. Tropical regions will see larger changes than temperate regions, and summer heat waves will lengthen more than winter warm spells. Researchers led by UCLA and the Universidad Adolfo Ibañez in Santiago, Chile, developed an equation that has the flexibility to analyze one region or to gain additional broad insight by analyzing multiple regions as a whole. New research finds that not only will climate change make ...

New mathematical insights into Lagrangian turbulence

2025-07-08
A sneeze. Ocean currents. Smoke. What do these have in common? They’re instances of turbulence: unpredictable, chaotic, uneven fluid flows of fluctuating velocity and pressure. Though ubiquitous in nature, these flows remain somewhat of a mystery, theoretically and computationally. “Most flows that we encounter in nature are turbulent — it does not matter whether it is the flow outside the airplane that makes us fasten our seatbelts, or the flow in a small stream,” said UC Santa Barbara mathematics professor Björn Birnir. “Turbulence is difficult to understand because the mathematical ...

Clinical trials reveal promising alternatives to high-toxicity tuberculosis drug

2025-07-08
The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile compared to linezolid, with potential to replace this current cornerstone in the treatment of drug-resistant TB. The findings were published on 7 July in two peer-reviewed articles in The Lancet Infectious Diseases, one of the world’s leading journals in the field of infectious disease medicine. Research partners in Europe included Radboud university medical center from the Netherlands and the German Center for Infection Research (DZIF), Munich, the Fraunhofer Institute for Translational Medicine and Pharmacology ...

Artificial solar eclipses in space could shed light on Sun

2025-07-08
Recreating artificial solar eclipses in space could help astronomers decipher the inner workings of our Sun much quicker than if they had to wait for the celestial show on Earth. The plan, part of a UK-led space mission to be unveiled at the Royal Astronomical Society’s National Astronomy Meeting 2025 in Durham, would involve the use of a mini-satellite and the Moon's shadow to achieve the closest-ever views of the Sun's atmosphere. The Moon-Enabled Sun Occultation Mission (MESOM) proposes a novel way to study the inner solar corona – the innermost layer of the Sun's atmosphere, which ...

Probing the cosmic Dark Ages from the far side of the Moon

2025-07-08
Royal Astronomical Society press release RAS PR 25/26 (NAM 6) 8 July 2025 Embargoed until Wednesday 9 July 2025 at 00:01 BST Astronomers want to unlock the secrets of the 'Cosmic Dawn' by sending a miniature spacecraft to listen out for an "ancient whisper" on the far side of the Moon. The proposed mission will study the very early universe, right after the Big Bang, when it was still quite dark and empty before the first stars and galaxies appeared. But to probe the cosmic 'Dark ...

UK hopes to bolster space weather forecasts with Europe's first solar storm monitor

2025-07-08
Royal Astronomical Society press release RAS PR 25/27 (NAM 7) 8 July 2025 Embargoed until Wednesday 9 July 2025 at 00:01 BST A new UK-led satellite mission concept aims to strengthen the country's position in space weather observation and forecasting by deploying a suite of homegrown scientific instruments on a low-cost spacecraft in low-Earth orbit. The proposal is being presented today (Wednesday) at the Royal Astronomical Society's National Astronomy Meeting 2025 in Durham. UK-ODESSI ...

Can one video change a teen's mindset? New study says yes - but there’s a catch

2025-07-08
A mental health hack designed to promote mental well-being could shift how teenagers view themselves – according to new research from the University of East Anglia. A new study published today shows how watching a one-off ten-minute video can positively change young people’s beliefs about their personality traits. But the intervention appeared to have little immediate effect on symptoms of anxiety or depression. The findings add to a growing body of evidence that mental health support delivered online can play a valuable role - but may work best as part of a broader toolkit of services. The team say that more ...

How lakes connect to groundwater critical for resilience to climate change, research finds

2025-07-08
Understanding whether lakes are fed predominantly by groundwater or rainwater is critical to managing our water resources in the face of droughts and shortages, new research has found. The study drew on data from 350 lakes across 18 European countries, collected between 2022 and 2024, to provide a comprehensive picture of how the continent’s lakes are coping with climate change. The research is presented today [Wednesday 9 July, 2025] at the Goldschmidt Conference in Prague. The researchers, from the Czech Academy of Sciences, analysed the proportions of stable hydrogen and oxygen isotopes (18O and 2H) in the lakes’ ...

Youngest basaltic lunar meteorite fills nearly one billion-year gap in Moon’s volcanic history

2025-07-08
A 2.35-billion-year-old meteorite with a unique chemical signature, found in Africa in 2023, plugs a major gap in our understanding of the Moon’s volcanic history.   Presented today [Wednesday 9 July] at the Goldschmidt Conference in Prague, findings from analyses of the Northwest Africa 16286 meteorite offer fresh insights into how the Moon’s interior evolved, highlighting the long-lived nature of its volcanic activity. Analyses by researchers from the University of Manchester, UK, lend weight to a theory that the Moon retained internal heat-generating processes that powered ...

LAST 30 PRESS RELEASES:

People with ‘young brains’ outlive ‘old-brained’ peers, Stanford Medicine scientists find

Make-your-own weight-loss drug using an innovative genome editing approach

Cancer is extremely rare in turtles, finds a new study

AI used to create protein that kills E. coli

Major autism study uncovers biologically distinct subtypes, paving the way for precision diagnosis and care

Study shows how AI could help pathologists match cancer patients to the right treatments—faster and more efficiently

Implantable device could save diabetes patients from dangerously low blood sugar

Need a new 3D material? Build it with DNA

New study reveals subclasses of autism by linking traits to genetics

The right mix and planting pattern of trees enhance forest productivity and services

Coral calcification benefits from human hormone injections

New “bone-digesting” cell type discovered in pythons

New study points to Skagerrak as nursery area for the enigmatic Greenland shark

Are sewage spills and coastal winds contributing to airborne microplastics?

Which factors affect the success of popular prescription weight loss drugs in individuals?

Do renter protection policies reduce rental housing discrimination?

Does grading students at earlier ages increase the risk of mental disorders in adolescents?

New artificial intelligence–based test detects early signs of osteoporosis from X-ray images

Can eating a healthy plant-based diet help protect against inflammatory bowel disease?

Do local voting rights affect migrants’ participation in protests?

Mysterious ‘Dark Dwarfs’ may be hiding at the heart of the Milky Way

Real-world data shows teclistamab can benefit many multiple myeloma patients who would have been ineligible for pivotal trial

Scientists reveal how a key inflammatory molecule triggers esophageal muscle contraction

Duration of heat waves accelerating faster than global warming

New mathematical insights into Lagrangian turbulence

Clinical trials reveal promising alternatives to high-toxicity tuberculosis drug

Artificial solar eclipses in space could shed light on Sun

Probing the cosmic Dark Ages from the far side of the Moon

UK hopes to bolster space weather forecasts with Europe's first solar storm monitor

Can one video change a teen's mindset? New study says yes - but there’s a catch

[Press-News.org] Real-world data shows teclistamab can benefit many multiple myeloma patients who would have been ineligible for pivotal trial
Retrospective study revealed efficacy of the bispecific T-cell engager in patients with high-risk, heavily pretreated multiple myeloma, including after prior BCMA therapy